XML 60 R54.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments and Contingencies - Additional Information (Details) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | ---
Nov. 29, 2024 USD ($) | Jun. 30, 2022 USD ($) | Sep. 30, 2025 USD ($) Item | Sep. 30, 2024 USD ($) | Sep. 30, 2025 USD ($) Item | Sep. 30, 2024 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |
Research and development |  |  | $ 39,951,000 | $ 33,226,000 | $ 114,477,000 | $ 92,218,000
Novartis Pharma Agreement |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Exclusive negotiation period after receipt of written notice | 30 days |  |  |  |  |
Exclusive negotiation period maximum | 120 days |  |  |  |  |
Proposed sale negotiation period | 45 days |  |  |  |  |
Aggregate amount of units actually supplied | $ 275,000,000 |  |  |  |  |
Novartis Pharma Agreement | Bio Medical Research Inc |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Number of patients | Item |  |  | 60 |  | 60 |
Aurigene Agreement |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Milestone payments to be paid to collaborative partner |  | $ 60,000,000 |  |  |  |
Upfront payment, research and development. |  | 8,000,000 |  |  |  |
Research and development |  |  |  |  | $ 10,000,000 |
Aurigene Agreement | Commercial Milestone |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Milestone payments to be paid to collaborative partner |  | $ 370,000,000 |  |  |  |
Aurigene Agreement | Clinical Cevelopment and Regulatory Milestones |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 5,000,000

X
- Definition Aggregate value of units actually supplied. + References No definition available. + Details
Name: | olma_AggregateValueOfUnitsActuallySupplied
Namespace Prefix: | olma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition In the aggregate, the maximum milestone payments to be paid to the collaborative partner. + References No definition available. + Details
Name: | olma_CollaborativeArrangementAggregateMaximumMilestonePaymentsToBePaidToCollaborativePartner
Namespace Prefix: | olma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exclusive negotiation period after receipt of written notice. + References No definition available. + Details
Name: | olma_ExclusiveNegotiationPeriodAfterReceiptOfWrittenNotice
Namespace Prefix: | olma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exclusive negotiation period maximum. + References No definition available. + Details
Name: | olma_ExclusiveNegotiationPeriodMaximum
Namespace Prefix: | olma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patients. + References No definition available. + Details
Name: | olma_NumberOfPatients
Namespace Prefix: | olma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Proposed sale negotiation period. + References No definition available. + Details
Name: | olma_ProposedSaleNegotiationPeriod
Namespace Prefix: | olma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represent expenses related to upfront research and development. + References No definition available. + Details
Name: | olma_UpfrontPaymentResearchAndDevelopmentExpenses
Namespace Prefix: | olma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=olma_NovartisPharmaAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=olma_BioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=olma_AurigeneAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | olma_MilestoneAchievementAxis=olma_CommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | olma_MilestoneAchievementAxis=olma_ClinicalDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |